Login to Your Account


Would-'B' blockbuster? Nephrogenex advances pyridoxamine phase III

By Randy Osborne
Staff Writer

Friday, June 20, 2014
Sold as a nutritional supplement – before it was ruled a drug by the FDA and went through phase II trials in the hands of Biostratum Inc. – pyridoxamine dihydrochloride entered a pivotal program overseen by Nephrogenex Inc., which is testing the derivative of vitamin B6 (pyridoxine) in diabetic nephropathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription